Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024  


Read the rest here:
Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024  

Related Posts